Современные возможности управления сахарным диабетом типа 2

1. Khaw K, Wareham N, Bingham S et al. Association of Hemoglobin A1c with Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk. Ann Intern Med 2004; 141(6): 413–21.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group. Lancet 1998; 352 (9131): 837–53.
3. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321 (7258): 405–12.
4. Patel A, MacMahon S, Chalmers J et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358 (24): 2560–72.
5. Kahn SE, Haffner SM, Heise MA et al. For the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427–43.
6. Turner RC, Cull CA, Frighi V, Holman RR. For the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement. JAMA 1999; 281: 2005–12.
7. Turner R, Millns H, Neil H et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998: 316: 823–8.
8. ADA. Standards of medical care in diabetes – 2009. Diabetes Care 2009; 32 (Suppl. 1): 13–61.
9. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions and clinical implications. Am J Med 2011. 124 (Suppl. 1): 3–18.
10. Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15: 540–59.
11. Nathan DM, Buse JB, Davidson MB, Ferrannini E et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193–203.
12. Rodbard HW, Jellinger PS, Davidson JA et al. AACE/ACE diabetes algorithm for glycemic control, 2009 [article online]. Available from https://www.aace.com/sites/default/files/GlycemicControlAlgorithm.pdf. Accessed 17 November 2011/
13. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55: 1577–96.
14. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Вып. 5. Под ред. И.И.Дедова, М.В.Шестаковой. Сахарный диабет. 2011; 4 (Прил.).
15. Degn KB, Juhl CB, Sturis J et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53(5): 1187–94.
16. Marre M, Shaw J, Brandle M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268–78.
17. Nauck MA, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). The LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009; 32: 84–90.
18. Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473–81.
19. Zinman B, Gerich J, Buse JB et al. Efficacy and safety of the human GLP-1 analogue liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1224–30.
20. Russell-Jones D, Vaag A, Schmitz O et al; on behalf of the LEAD-5 met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia 2009; 52: 2046–55.
21. Buse JB, Rosenstock J, Sesti G et al. For the LEAD 6 Study Group. A study of two glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: liraglutide once daily compared with exenatide twice daily in a randomised, 26-week, open-label trial (LEAD-6). Lancet 2009; 374: 39–47.
22. Pratley RE, Nauck M, Bailey T et al. For the 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin in patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447–56.
23. Nauck MA, Vaag A, Colagiuri S et al. HbA1c reduction with liraglutide in type 2 diabetes patients is associated with initial HbA1c levels. International Diabetes Federation—20th World Diabetes Congress 2009; P–1400.
24. Henry RR, Buse JB, Sesti G et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A1c: a meta-analysis of the liraglutide development program. Endocr Pract. 2011; 17(6): 906–13.
25. Holst JJ, Nauck M, Brett J et al. Improvement in glycaemic control when adding liraglutide to existing therapy: results from a meta-analysis of six large randomised clinical trials. Diabetologia 2009; 52 (Suppl. 1): 288.
26. Buse JB, Sesti G, Schmidt WE et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010; 33 (6): 1300–3.
27. Pratley RE et al. Diabetes 2011; 60 (Suppl. 1): 1119.
28. Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010; 86: 44–57.
29. Vilsbøll T, Christensen M, Junker AE et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012; 344: d7771 doi: 10.1136/bmj.d7771.
30. Reid T. Choosing GLP-1 receptor agonists or DPP-4 inhibitors: weighing the clinical trial evidence. Clin Diabetes 2012; 30 (1): 3–12.
31. Meneghini LF, Orozco-Beltran D, Khunti K et al. Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab 2011; 96 (11): 3337–53.
32. Ismail MH. Nonalcoholic fatty liver disease and type 2 diabetes mellitus: the hidden epidemic. Am J Med Sci 2011; 341: 485–92.
33. Gilbert MP, Pratley RE. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. Am J Med 2009; 122 (6A): 11–24. 
34. Zinman B, Colagiuri S, Madsbad S et al. The human GLP-1 analog, liraglutide, improves BMI and waist circumference in patients with type 2 diabetes: meta-analysis of six phase 3 trials. Diabetes 2010; 59 (Suppl. 1): A495 (1894-P).
35. Karagiannis T, Paschos P, Paletas K et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012; 344: e1369 doi:10.1136/bmj.e1369 (Published 12 March 2012).
36. Bergenstal RM, Wysham C, Macconell L et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376: 431–9.
37. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patient with hypertension: principal results of Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 35 (9118): 1755–62.
38. Patel A, ADVANCE Collaborative Group, MacMahon S et al. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomice controlled trial. Lancet 2007; 370 (9590): 829–40.
39. Fonseca V, Madsbad S, Falahati A. Once daily human GLP-1 analog liraglutide reduces systolic blood pressure: a metaanalysis of six clinical trials (LEAD). Diabetes 2009; 58 (Suppl. 1): A146.
40. Zinman B. Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time? Am J Med 2011; 124: 19–34.
41. Garber A. Incretin effects on b-cell function, replication, and mass. Diabetes Care 2011; 34 (Suppl. 2): 258–63.
42. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009; 32 (5): 834–8.

Г.Р.Галстян, М.В.Шестакова 

ФГБУ Эндокринологический научный центр Минздрава РФ, Москва